Skip to main content
. 2008 Jun 30;2(1):39–46. doi: 10.5009/gnl.2008.2.1.39

Fig. 3.

Fig. 3

Effect of subcutaneous administration of CGS-21680 on zymosan-induced visceral hyperalgesia (A) and result of statistical analysis (B). CGS-21680 attenuates VMR to CRD at doses of 30 mg and 100 mg (p<0.05) but not at 10 mg. At high dose, hindlimb weakness is produced (*p<0.05).

VMR, visceromotor response; CRD, colorectal distension.